A Look At Elevance Health (ELV) Valuation After Strong Q4 Results Dividend Hike And Leadership Changes

Simply Wall St.10:23

Elevance Health (ELV) is back in focus after strong fourth quarter earnings, a higher dividend, updated full year guidance, and a flurry of senior appointments across its Health Benefits and Carelon ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2625648776?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/160077-main-header/1756254056160","is_english":true,"pubTime":"2026-04-05 10:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625648776","market":"us","top_or_hot":-1,"title":"A Look At Elevance Health (ELV) Valuation After Strong Q4 Results Dividend Hike And Leadership Changes","media":"Simply Wall St.","content":"<div>\n<p>Elevance Health (ELV) is back in focus after strong fourth quarter earnings, a higher dividend, updated full year guidance, and a flurry of senior appointments across its Health Benefits and Carelon ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-elv/elevance-health/news/a-look-at-elevance-health-elv-valuation-after-strong-q4-resu\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Elevance Health (ELV) Valuation After Strong Q4 Results Dividend Hike And Leadership Changes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Elevance Health (ELV) Valuation After Strong Q4 Results Dividend Hike And Leadership Changes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-05 10:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-elv/elevance-health/news/a-look-at-elevance-health-elv-valuation-after-strong-q4-resu><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Elevance Health (ELV) is back in focus after strong fourth quarter earnings, a higher dividend, updated full year guidance, and a flurry of senior appointments across its Health Benefits and Carelon ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-elv/elevance-health/news/a-look-at-elevance-health-elv-valuation-after-strong-q4-resu\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0980610538.SGD","symbol_name":"Natixis Harris Associates US Equity RA SGD-H","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-elv/elevance-health/news/a-look-at-elevance-health-elv-valuation-after-strong-q4-resu","article_id":"2625648776","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/160077-main-header/1756254056160"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-elv/elevance-health/news/a-look-at-elevance-health-elv-valuation-after-strong-q4-resu","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2625648776","pubTimestamp":1775355789,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Elevance Health (ELV) is back in focus after strong fourth quarter earnings, a higher dividend, updated full year guidance, and a flurry of senior appointments across its Health Benefits and Carelon units.\nSee our latest analysis for Elevance Health.\nThe recent leadership reshuffle, strong fourth quarter results, higher dividend, and updated guidance have helped the share price rebound, with a 7 day share price return of 5.01% and a 30 day share price return of 4.98%. However, the 1 year...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","ELV":"Elevance Health","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU2592432038.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"A\" (USD) ACC","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","ELV.AU":"ELEVRA LITHIUM LTD","LU0058720904.USD":"联博国际健康护理基金A","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","LU2108987350.USD":"UBS (LUX) EQUITY SICAV GLOBAL OPPORTUNITY SUSTAINABLE (USD) \"P\" (USD) ACC","LU0048573561.USD":"FIDELITY AMERICA \"A\" (USD) INC","LU0314106906.USD":"MANULIFE GF GLOBAL EQUITY \"AA\" (USD) INC","LU2430703178.SGD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (SGDHDG) INC","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","LU0251131958.USD":"FIDELITY AMERICA \"A\" (USD) ACC","LU0068578508.USD":"First Eagle Amundi International Cl AU-C USD","LU2430703251.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (USD) INC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BK4585":"ETF&股票定投概念","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU2505996681.GBP":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (GBPHDG) INC","LU0433182093.SGD":"First Eagle Amundi International AS-C SGD","LU0061474960.USD":"天利环球焦点基金AU Acc","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU2505996509.AUD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (AUDHDG) INC","LU0878866978.SGD":"First Eagle Amundi International AHS-QD SGD-H","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","BK4588":"碎股","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4154":"管理型保健护理","LU0957791311.USD":"THREADNEEDLE (LUX) GLOBAL FOCUS \"ZU\" (USD) ACC","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU0882574055.USD":"富达全球健康医疗A ACC"},"translate_title":"第四季度业绩强劲、股息上调和领导层变动后Elevance Health(ELV)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELV.AU":1.5,"ELV":1.5},"content_text":"Elevance Health (ELV) is back in focus after strong fourth quarter earnings, a higher dividend, updated full year guidance, and a flurry of senior appointments across its Health Benefits and Carelon units. See our latest analysis for Elevance Health. The recent leadership reshuffle, strong fourth quarter results, higher dividend, and updated guidance have helped the share price rebound, with a 7 day share price return of 5.01% and a 30 day share price return of 4.98%. However, the 1 year total shareholder return decline of 28.38% and 5 year total shareholder return decline of 10.60% point to longer term underperformance and fading momentum. If Elevance Health's earnings and leadership news has your attention, it can be useful to compare it with other healthcare names using our screener for 36 healthcare AI stocks With Elevance Health trading at $300.74, an implied 27% discount to analyst targets of around $381 and a value score of 6, the key question is whether the recent weakness offers an entry point or whether the market is already pricing in future growth. AdvertisementMost Popular Narrative: 23% Undervalued According to the most followed narrative, Elevance Health's fair value sits at $390.54 versus the last close of $300.74, implying meaningful upside in the model before the latest price recovery.  As a potential growth investment, Elevance Health offers a compelling mix of undervaluation and long-term growth drivers, particularly in the Medicare Advantage and value-based care segments. While near-term risks like Medicaid enrollment declines and cost pressures pose challenges, its diversified revenue base and focus on innovation provide resilience.  Read the complete narrative. Curious what supports that higher fair value? The narrative leans on steadier earnings expansion, firmer margins, and a future profit multiple that assumes Elevance can narrow the gap with larger peers. Result: Fair Value of $390.54 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, that upside view still hinges on Elevance containing medical costs and stabilising Medicaid membership pressures, which previously weighed on earnings and valuation. Find out about the key risks to this Elevance Health narrative. Next Steps All this leaves the mood mixed, so do not wait for consensus. Instead, check the data yourself and weigh what matters most to you with 5 key rewards Ready for more investment ideas? If Elevance Health has sharpened your focus, do not stop here. Use the Simply Wall St Screener to quickly spot fresh opportunities that match your style.  Target resilient compounders by scanning companies with strong finances and steady profiles using our 68 resilient stocks with low risk scores Hunt for quality at a discount by checking out companies trading below their estimated worth through the 59 high quality undervalued stocks Lock in potential income streams by reviewing companies with robust payouts inside the 13 dividend fortresses   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Elevance Health might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2625648776","isCrawlerRequest":true}